Plenary Session: Immunotherapy in Combination, 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
covers in REAL TIME
2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA
In Attendance, steaming LIVE using Social Media
Aviva Lev-Ari, PhD, RN
Editor-in-Chief
http://pharmaceuticalintelligence.com
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
https://www.massbio.org/events/2016-massbio-annual-meeting-1120
2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA
Plenary Session: Immunotherapy in Combination
- Pamela Esposito – Moderator, Cancer vaccine space
- synergies multiple agents,
- tolerability long tem will be an issue
- John Orloff, Executive Vice President, Head of Research & Development and Chief Scientific Officer, Baxalta
- CAR-T combined with PD1
- Combination is the future
- Partnering wiht other companies
- Will not build a Biomarker group, rely on others
- seelct tumors based on tumor tissues in Ovarian cancer
- late stage acquisitions at Phase iii only
- R&D sparing when acquision id at Phase II then Development is taken in House
- On the shelf manufacturing approach
- Mix later stage and early internal stage
- Pancreatic Cancer partner when all other focused on immune oncology
- Precision Medicine partner, willingness to collaborate
- complementary expertise in hematology with research discovery teanslational expertise
- to get in the door of immuno oncology partnerships and acquisition
- new targets challenge for FDA
- Helen Sabzevari, CSO & Co-Founder, Compass Therapeutics
- PD and PD1 – not a monotherapy, combination therapy is a must check point inhibitor
- Pathways
- Genomics, Proteomics, predictive markers,
- identify the combination
- NIH works on Cancer Vaccine
- Personalized Vaccine will be part of the combination therapy
- Immune system : Macrophages, T- cells memory,
- Immune-therspy is done in combination will be the future of Oncology – Biologics
- Compass Therapeutics – will be have in 2016 the largest Portfolio of Immuno-Onclogy targets
- Target discovery to the Clinic
- TRanslational Biomarket – intrenal Group collaborationwith clinical centers
- gene sequence each patient
- Immuno oncollogy is revolutionizing the Oncology THE CORNERSTONE – because RESPONSES that no radiation therapy has achieved are achieved by Immuno therapy
- Lower toxicity, higher cure rates
- Destroy the field or be successful
- standard therapy not every chemo can be combined
- Pressure from Regulatory
- Pressure on Pricing
- Toxicity: what is been combining
- 450 CLinical Trial in PD and combinations
- PRECISION IMMUNOLOGY
- targets that must be biospecific
- tumor microenvironment
- Robert Ang
- Cancer Vaccines
- Agonists, Immune system can’t be compromised to response to immouno therapy,
- Targeted approach with vaccine or bestepitope of C presentation, mutation expressed mount immuno agains it
- T cell level, checkpoint will be necessary for late satge PD1 – Start with BMS,
- Combinations of PD-1
- PSA – is tolerant – no ideal target
- Biomarkers is critical
- Tumor heterogeneity synergies with vaccine targeting technologies, adjavent with check point
- Tumor level was not researched enough T-Cells in peripheral blood
- funded last year, BMS collaboration DRUG for DATA not selling assets
- T-Cells in solid Tumors
- Nordik transaction over 14 months, mutual beneficial trend,
- BMS – invested in Immune Oncology need to complement and think broadly in vaccine, Phase III will determine
- Integrity of the portfolio, partnership are needed for scientific vision to realize the power of the portfolio
- deal with Pfizer, clinical effort $850Million and $2Billion to come – molecule is the differentiator
- data depend on strategy each specific deal
- Immuno combinations to bring cure, the future of that is still fare
- Immuno-Oncology is the revolution
- Progression in tumor, monitoring
- adverse event and quality of life must be integrated beyonf longer life wiht 12 month
Questions from the Floor
- populations comorbidity
- BIOSPECIFIC, TRIAL SPECIFIC
- HUMANIZATION
- Tolerability – side effects
Leave a Reply